Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cloratadd D
- Development stage
- Phase 1
- Lead developer
- EMS
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Cloratadd D is a fixed-dose combination drug product containing loratadine and pseudoephedrine sulfate, developed by EMS S/A and evaluated in clinical trials by Azidus Brasil. Loratadine is a long-acting, non-sedating tricyclic antihistamine that selectively antagonizes peripheral histamine H1 receptors. Pseudoephedrine sulfate is an orally active sympathomimetic amine that exerts a decongestant effect on the nasal mucosa by acting as an agonist at alpha-adrenergic receptors, leading to vasoconstriction. The combination is primarily indicated for the relief of symptoms associated with allergic rhinitis, including nasal congestion, sneezing, rhinorrhea, and lacrimation.
- Brand names
- Cloratadd D
- Other names
- loratadine + pseudoephedrine sulfate
02
Targets
ADRA1A (α1A)ADRA2A (α2A)HRH1 (Histamine H1 Receptor)ADRA1 (Alpha-1 adrenergic receptor family)
Beyond the preview
Go deeper on Cloratadd D.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cloratadd D.